Krunal Vishavadia Krunal Vishavadia, Sandip Solanki Sandip Solanki, Hiren Prajapati Hiren Prajapati, Madhu Sharma Madhu Sharma
Gujarat Technological University, Ahmedabad, India.
SIIB, Pune, Maharashtra, India.
Urologiia. 2023 May(2):66-72.
To assess the prescribing practices for overactive bladder (OAB) pharmacotherapy based on the prescription trend analysis across different specialties of India.
s: IQVIA (Quintiles and IMS Health) secondary sales audit (SSA), as well as a prescription audit for antimuscarinics and beta-3 adrenoceptor agonists (mirabegron) from 2014 to 2021, were analyzed. The data includes SSA data of various antimuscarinics like solifenacin, oxybutynin, tolterodine, darifenacin, trospium and mirabegron change in the prescription trend of antimuscarinics and mirabegron across different specialties; prescribers overlap analysis for solifenacin and mirabegron among Indian urologists were also analyzed.
Urologists prescription rates of OAB drugs were 65% in 2016 and 54% in 2021. The rate of OAB medication prescription by non-urologist was highest from the surgeon (11%), followed by gynecologists (9%) and consultant physicians (8%) in 2021. In addition, among OAB medication prescription rates for antimuscarinics were 100% in 2016 and 58% in 2021 whereas for mirabegron, it was 0% in 2016 and 42% in 2021. Solifenacin was most frequently prescribed anticholinergics, followed by oxybutynin, tolterodine, darifenacin, and trospium. The proportion of prescribers of OAB medication among urologists was 38% in 2016 and 33% in 2021. Exclusive prescribers of solifenacin were 748 in 2018 and 739 in 2021 at the urologist, whereas for mirabegron, it was 961 in 2018 and 934 in 2021. The compound annual growth rate for prescription of the last 6 years (from 2016-2021) for solifenacin and mirabegron was -3% and 8% respectively.
Urology remained a top prescribing specialty for OAB drugs, although prescription share increased at surgeon and consultant physician. OAB medicines prescriptions by urologists are shifting from leading antimuscarinic solifenacin to beta-agonist mirabegron. Data from this study will ultimately lead to the OAB medication preference by the specialist that could lead to more advanced OAB management.
基于印度不同专业的处方趋势分析，评估膀胱过度活动症（OAB）药物治疗的处方实践。
分析了IQVIA（昆泰公司和艾美仕市场研究公司）的二次销售审计（SSA）以及2014年至2021年抗毒蕈碱药物和β-3肾上腺素能受体激动剂（米拉贝隆）的处方审计。数据包括各种抗毒蕈碱药物（如索利那新、奥昔布宁、托特罗定、达非那新、曲司氯铵）的SSA数据以及米拉贝隆在不同专业中抗毒蕈碱药物和米拉贝隆处方趋势的变化；还分析了印度泌尿科医生中索利那新和米拉贝隆的开处方者重叠情况。
泌尿科医生开具OAB药物的比例在2016年为65%，在2021年为54%。2021年，非泌尿科医生中开具OAB药物比例最高的是外科医生（11%），其次是妇科医生（9%）和顾问医生（8%）。此外，抗毒蕈碱药物的OAB药物处方率在2016年为100%，在2021年为58%，而米拉贝隆在2016年为0%，在2021年为42%。索利那新是最常开具的抗胆碱能药物，其次是奥昔布宁、托特罗定、达非那新和曲司氯铵。泌尿科医生中开具OAB药物的开处方者比例在2016年为38%，在2021年为33%。2018年泌尿科医生中索利那新的独家开处方者有748人，2021年有739人，而米拉贝隆在2018年有961人，2021年有934人。索利那新和米拉贝隆在过去6年（2016 - 2021年）的处方复合年增长率分别为-3%和8%。
尽管外科医生和顾问医生的处方份额有所增加，但泌尿科仍然是OAB药物的主要开处方专业。泌尿科医生开具的OAB药物正从领先的抗毒蕈碱药物索利那新转向β-激动剂米拉贝隆。本研究的数据最终将导致专科医生对OAB药物的偏好，从而实现更先进的OAB管理。
